References

• Rohner, H., Gaspar, N., Philipsen, A., & Schulze, M. (2023). Prevalence of attention deficit hyperactivity disorder (ADHD) among substance use disorder (SUD) populations: Meta-analysis. International Journal of Environmental Research and Public Health, 20(2), Article 1275. https://doi.org/10.3390/ijerph20021275
• Barbuti, M., Maiello, M., Spera, V., Pallucchini, A., Brancati, G. E., Maremmani, A. G. I., Perugi, G., & Maremmani, I. (2023). Challenges of treating ADHD with comorbid substance use disorder: Considerations for the clinician. Journal of Clinical Medicine, 12(9), Article 3096. https://doi.org/10.3390/jcm12093096
• Crunelle, C. L., van den Brink, W., Moggi, F., Konstenius, M., Franck, J., Levin, F. R., van de Glind, G., Demetrovics, Z., Coetzee, C., Luderer, M., Schellekens, A., ICASA consensus group, & Matthys, F. (2018). International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. European Addiction Research, 24(1), 43–51. https://doi.org/10.1159/000487767